- Policy
- Negotiations on the Brukinsa price have begun
- by Lee, Tak-Sun Feb 28, 2023 05:52am
- Crysvita and Dupixent are also negotiating drug prices. It has been found that Chinese pharmaceutical company BeiGene Korea has entered into drug price negotiations with the NHIS for Brukinsa capsules 80mg sold domestically. When the NHIS drug price negotiation is completed, the drug will be covered through a report to the Health Insurance Po
- Company
- Will Tagrisso finally be reimbursed with public support?
- by Eo, Yun-Ho Feb 28, 2023 05:52am
- The D-day has finally been revealed. Will the lung cancer treatment ‘Tagrisso’ finally succeed in extending reimbursement to the first line? According to industry sources, AstraZeneca’s EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment Tagrisso will be deliberated at the Health Insurance Review and Assessment Service
- Company
- Daiichi Sankyo Korea appoints Jeongtae Kim as new CEO
- by Eo, Yun-Ho Feb 27, 2023 05:57am
- Daiichi Sankyo Korea appointed Vice President Kim Jung-tae (49) as the new CEO. Daiichi Sankyo announced on the 20th that it will appoint Vice President Kim Jeong-tae as the new CEO and President Kim Dae-jung will retire on March 31. Accordingly, from April 1st, President Kim Dae-jung will support the company as an advisor, and new President
- Product
- Daewoong/Novartis promise to cooperate
- by Kim JiEun Feb 27, 2023 05:57am
- On the 22nd, the Korea Pharmaceutical Association (Chairman Choi Kwang-Hoon) disused stock medicine return TF (Team Leader Jung Hyeon-cheol) held a meeting with Daewoong Pharmaceutical and Novartis Korea regarding the return of unused stock medicine and announced that they had agreed to actively cooperate in a settlement. In the case of Daewo
- Company
- Sales of 26-year-old Gemzar·Zyprexa show rebound
- by Kim, Jin-Gu Feb 27, 2023 05:57am
- The anticancer drug ‘Gemzar‘ and schizophrenia drug ‘Zyprexa' Boryung Pharmaceutical had acquired domestic sales and licensing lights of have enjoyed a rebound in sales. Sales of both drugs had been on a downfall prior to Boryung’s acquisition. Therefore, the analysis is that Boryung’s active portfolio expansion strategy and
- Opinion
- [Reporter's view] Implications of Lucentis biosimilar
- by Lee, Tak-Sun Feb 27, 2023 05:57am
- The domestic prescription drug market is not a market where prices can operate with competitiveness. This is because paying patients do not have the option to choose a product, and doctors who have the option do not have a margin on sales of insurance drugs, so there is little incentive to prescribe low-priced products. Because of this, even
- Company
- Will Luxturna will be deliberated by DREC for reimb?
- by Eo, Yun-Ho Feb 27, 2023 05:56am
- Industry attention is focused on whether progress will be made in discussions for the reimbursement of the one-shot retinal dystrophy treatment Luxturna. It was found that it is highly likely that Novartis Korea’s Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) will be presented as an agenda for deliberation
- Policy
- The value of pharmaceutical bio innovation is reflected
- by Lee, Jeong-Hwan Feb 24, 2023 05:53am
- Second Vice Minister of Health and Welfare Park Min-soo promised to support the biopharmaceutical sector by implementing drug pricing policies that reflect innovative values and improving the certification system for innovative pharmaceutical companies. Vice Minister Park also asked biopharmaceutical companies to make efforts to create blockb
- Opinion
- [Reporter’s View] Decide whether to offer free HCV testing
- by Jung, Sae-Im Feb 24, 2023 05:53am
- Eight years have passed since discussions began on adding hepatitis C (HCV) screening as a free item in Korea’s national health examination program. Despite various supporting evidence that was produced during the period, including the feasibility study that started in 2016, and an analysis that showed that it was cost-effective to include
- Company
- US approval of Celltrion Yuflyma was delayed
- by Feb 24, 2023 05:53am
- Celltrion has confirmed that the U.S. Food and Drug Administration (FDA) will complete the Yuflyma final approval review by May of this year. Celltrion announced on the 23rd that it had confirmed that the final approval review of Yuflyma would be completed by May of this year while continuing discussions with the FDA. Earlier, the U.S. approv
